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Abstract
A dietary supplement (AP, Armolipid Plus) that combines red yeast rice extract, policosanol, berberine, folic acid, coenzyme
Q10 and asthaxantine can have beneficial effects on cardiovascular disease (CVD) biomarkers. The aim of this study was to
assess whether the intake of AP, in combination with dietary recommendations, reduces serum low density lipoprotein
cholesterol (LDL-c) concentrations and other CVD biomarkers in patients with hypercholesterolemia. Eligible patients were
recruited from the outpatient clinics of six Spanish hospitals Hospital Virgen del Rocı́o (Sevilla); Hospital San Jorge (Huesca);
Hospital San Pedro (Logroño); Hospital Gregorio Marañón (Madrid), Hospital la Fe (Valencia) and Hospital Universitari Sant Joan
(Reus) as recruiting and coordinating center. 102 participants (mean age 6 SD; 50.91611.61; 32 men) with low CVD, with
mild-to-moderately elevated LDL-c (between 3.35 mmol/L and 4.88 mmol/L) without hypolipemic therapy were
randomized in a double-blind, parallel, controlled, multicenter trial commencing January 2012 and ending December
2012. Among the exclusion criteria were any concomitant chronic disease, triglycerides (TG) .3.97 mmol/L, pregnant or
lactating, and history of CVD. At 12 weeks, compared to placebo, AP reduced LDL-c by 26.9%, apolipoprotein (Apo) B-100
by 26.6% and total cholesterol/HDL-c ratio by 25.5%, the ApoB/ApoA1 ratio by 28.6%, while increasing ApoA1 by +2.5%
(p,0.05). AP consumption was associated with modest mean weight loss of 20.93 kg (95%CI: -1.74 to -0.12; P = 0.02)
compared with control group while dietary composition remained unchanged in the AP group. The AP product was well
tolerated. In conclusion, AP, combined with dietary recommendations, reduced LDL-c levels as well as total cholesterol/HDL-
c and ApoB/ApoA1 ratios, while increasing Apo A1, all of which are improvements in CVD risk indicators. AP is a product
which could benefit patients having moderate hyperlipidemia and excess body weight.
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Introduction
Cardiovascular diseases (CVD) are the principal cause of death
worldwide [1]. Among all the existing risk factors for CVD,
atherogenic dyslipidemia is considered preeminent [2-6].
Primary prevention of cardiovascular disease by identifying and
treating at-risk individuals remains a major public-health priority
[2–6]. The main pre-emptive approach is a healthy life-style,
assisted by pharmaco-therapy according to national and interna-
tional guidelines [2-6]. However, currently available drugs for
reducing CVD morbidity and mortality do not have the hoped-for
effectiveness in some patients and, as well, the adverse events of
the hypolipidemic drugs themselves need to be taken into account
PLOS ONE | www.plosone.org 1 August 2014 | Volume 9 | Issue 8 | e101978
[7]. Hence, some patients prefer not to receive drug treatment
because they are deeply concerned about possible side effects.
Considerable evidence is available to link several bioactive
dietary compounds with the reduction in CVD [8]. A dietary
supplement is a product that is orally consumed and which is
intended to supplement the usual diet to increase the intake of
ingredients reputed to have clinical benefit. These supplements
are, usually, an addition to the healthy diet, and not as a
conventional food or the sole item of a meal [9].
A dietary supplement (AP, Armolipid Plus, Rottapharm S.L.
Barcelona, Spain) has become commercially available and has
generated considerable research interest. It combines well-defined,
active, natural compounds such as red yeast rice extract,
policosanol and berberine (which decrease cholesterol and
triglycerides) folic acid (reduces homocysteine) and coenzyme
Q10 and asthaxantine (anti-oxidants). Recent data support the
efficacy of a monacolin K-berberine-policosanol (MBP) mixture as
a lipid lowering drug. The MBP mixture was developed and
clinically tested after evaluation of the lipid-lowering efficacy of
different mixtures of its components: monacolin K and policosanol
[10,11] and berberine and monacolin K [11]. Finally, MBP
consumed together with a standard Mediterranean healthy diet
appears to be able to reduce low-density lipoprotein cholesterol
(LDL)-c and triglyceride (TG) by a mean of 20% in different types
of patients [12].
Policosanol is a well-defined mixture of higher aliphatic primary
alcohols isolated from sugar cane wax, with cholesterol-lowering
effects proven for a dose range from 5-20 mg/day in patients with
type II hypercholesterolemia and dyslipidemia associated with
non-insulin dependent diabetes mellitus. There is scientific
evidence regarding the effect of policosanol as a lipid-lowering
agent [13,14]. Data from in vitro studies show that policosanol
inhibits hepatic cholesterol synthesis at the mevalonic acid stage of
the pathway. Increased hepatic LDL uptake, and increased serum
LDL catabolic rates, may also play a role. A systematic review and
meta-analysis of randomized controlled studies showed that
policosanol was safe, well tolerated and effective for LDL
reduction in patients with hyperlipidemia [14]. Controversially,
more recent randomized controlled trials do not demonstrate a
reduction in lipid levels after policosanol intake in patients with
hypercholesterolemia [15,16].
Red yeast is the product of fermentation of rice by the action of
the fungus Monascus purpureus. This fungus produces various
metabolic byproducts, including a red pigment (hence the name
red yeast), bacteriostatic products (i.e. able to inhibit bacterial
growth) and an active metabolite, monacolin K, which has been
proven to have a lipid lowering effect [17,18]. The quality of
monacolin present in red yeast depends on the strain of Monascus
purpureus and fermentation conditions. In the case of AP, the red
yeast is obtained under standardized conditions of a specific strain
of Monascus purpureus selected for optimum production of
monacolin K, the extent of which is defined and controlled.
Coenzyme Q10 is produced in the body starting from acetyl-
CoA in a multi-step process of the mevalonate pathway. The daily
2 mg supplementation of coenzyme Q10 provided by AP has been
considered sufficient. The rationale of AP is to combine natural
active ingredients with known effects on dyslipidemia at different
steps in human metabolism. Further, coenzyme Q10 and
astaxanthin are antioxidants that provide cell membranes with
protection against free radical and other oxidative attack [19]. The
purpose of adding folic acid to AP is to provide the product with a
component that is active against hyperhomocysteinemia [20].
Also, berberine, a constituent of AP tablets, has been described
as having produced a mild weight loss in obese human subjects
[21]. The overall benefit of AP appears to be an improvement in
CVD risk in populations with hyperlypidemia and medium-high
CVD risk [12,22-25]. The benefits of this dietary supplement have
not been studied in a population with early stages of lipid
alterations. Thus, the hypothesis is that AP has beneficial effects on
CVD biomarkers beyond that of lowering serum LDL-c concen-
trations. The aims of the present study were to assess whether the
addition of AP, in combination with dietary recommendations,
decreases the levels of LDL-c and other CVD biomarkers in
moderately hypercholesterolemic patients.
Subjects and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Design
The study was a multi-centered, randomized, double-blind,
placebo-controlled, two-arm study of the effect of AP in
individuals with mild-moderate hypercholesterolemia.
The study was approved by the Clinical Research Ethical
Committees of all participating centers. Protocols were according
to the Helsinki Declaration and good clinical practice guidelines of
the International Conference of Harmonization (ICH GCP). This
randomized trial was conducted according to extended CON-
SORT 2010 guidelines. The trial was registered with Clinical-
Trials.gov: number NCT01562080. The authors confirm that all
ongoing and related trials for this drug/intervention are registered.
There have not been any deviations from the study protocol. We
declare that there are no restrictions on sharing of data and/or
materials. All data and protocols are available from the
corresponding author, on request.
Participants and recruitment
Between January and April 2012, eligible patients were
recruited from the outpatient clinics of six hospitals (Hospital
Virgen del Rocı́o, Sevilla; Hospital San Jorge, Huesca; Hospital
San Pedro, Logroño; Hospital Gregorio Marañón, Madrid,
Hospital la Fe, Valencia) in Spain. The Hospital Universitari
Sant Joan de Reus was a recruiting and coordinating center. The
trial registration was completed in March 21, 2012 when all six
Hospitals confirmed their willingness to participate. Since some
administration processes were slower than others, some partici-
pating hospitals began recruiting volunteers (n = 118) within the 4-
month inclusion period envisaged. The end of study was October
2012.
All the investigators used the same standardized protocols,
written manuals, specific guidelines, and materials to train health-
care personnel to deliver uniform intervention. The protocol was
explained in a training session for all the investigators, and the
coordinating center clarified any questions and problems arising in
the course of the study follow-up. All participants provided written
informed consent prior to participation in the trial.
The participants were community-dwelling men and women
.18 years of age, with mild-moderately elevated LDL-c between
3.35 mmol/L [130 mg/dL] and 4.88 mmol/L [189 mg/dL], and
were candidates for lifestyle intervention without hypolipemic drug
treatment.
Among the exclusion criteria were diabetes mellitus, any
concomitant chronic disease, TG) .3.97 mmol/L (350 mg/dL),
pregnant or lactating, and a history of CVD.
Bioactive Compounds and Hypercholesterolemia
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Participant eligibility or exclusion was assessed by the attending
physician and was based on review of clinical records, followed by
a screening visit.
Randomization and intervention
The randomization code was computer generated. Participant
assignment to treatment or placebo arm was at a ratio of 1:1. The
number sequence for the subject, center, and treatment assign-
ment were allocated via an interactive electronic response system
hosted by the Nutrition and Health Technology Centre (CTNS).
The Unit responsible for the randomization took no further part in
the study.
After a 1-week baseline lead-in period, screened patients were
randomized to receive placebo (microcrystalline-cellulose) or 1
tablet/day of AP (Armolipid Plus, Rottapharm S.L., Barcelona,
Spain) as a dietary supplement. The AP tablets contain: red yeast
rice extract (200 mg), policosanol (10 mg), berberine (500 mg),
folic acid (0.2 mg), coenzyme Q10 (2 mg) and asthaxantine
(0.5 mg). The trial was for 12 weeks. Blinding was maintained
using matching placebo tablets which did not differ from the active
AP with respect to appearance or any other physical character-
istics.
Treatment monitoring of compliance was with a questionnaire
filled-in by patients at clinical interview. Consumption .80% was
considered an acceptable level of adherence.
During the intervention, dietary recommendations were
disseminated according to the guidelines of the Adult Treatment
Panel (ATP) III [5,6]. At basal and at the end of the clinical visits,
dietary compliance was monitored using 3-day dietary records,
and confirmed in interviews with the dietician.
The 10-year risk of CHD was calculated using the Framingham
Risk Score (FRS) at basal and the end of the outpatient visits.
Primary outcome was serum LDL-c concentrations. Secondary
outcomes included Total Cholesterol (TC), TG, HDL-c, apolipo-
protein (ApoA-1), apolipoprotein B-100 (ApoB-100), glucose,
insulin concentrations and HOMA-IR.
At each visit, standard anthropometric data were obtained while
participants were wearing lightweight clothing and no shoes.
Trained personnel measured weight and height using calibrated
scales and well-mounted stadiometer, respectively. Waist circum-
ference (WC) was measured midway between the lowest rib and
the iliac crest using an anthropometric tape. All participants were
advised to maintain their usual physical activity throughout the
study.
Measurements
A fasting blood sample was taken at 0 and another at week 12.
With the subject seated, BP was measured twice with a 1-min
interval in between, using an automatic sphygmomanometer. The
mean values were used in the statistical analyses.
Screening chemistries and hemogram were performed in each
of the participating centers with appropriate clinical chemistry
quality controls. All lipids and other biomarkers were measured
centrally at the Hospital Universitari Sant Joan, Reus (Catalunya,
Spain). Samples were stored at 280uC in the central laboratory’s
Biobanc (biobanc.reus@iispv.cat) until required for batched
analyses. TC, TG, HDL-c, apolipoprotein A-1 (ApoA-1), apoli-
poprotein B-100 (ApoB-100), and glucose measurements were
performed in serum using standard methods on an autoanalyzer
(Spinreact, Girona, Spain). LDL-c was calculated by means of the
Friedewald formula [26] Insulin was measured in serum using
specific ELISA kit (Mercodia AB, Uppsala, Sweden) and the
HOMA-IR was calculated [27].
Statistical analyses
The sample size of 50 subjects in each group was calculated
considering a Least Significant Difference (LSD) of 16 mg/dL
assuming that the common standard deviation was 28 mg/dL
using the Student t-test. Setting the bilateral significance level at
5%, the statistical power at 80% and assuming a level of losses of
15%, the total sample required was 116 subjects (58 subjects in
each group). We estimated that the minimum statistical difference
of 16 mg/dL, represents a sustainable 10% reduction in LDL-c
and is a substantial impact on cholesterol management; a
reduction that is similar to that of consuming soluble fiber or
fitosterols. If the mean LDL-c concentration of the participants
was 160 mg/dL the reduction expected will be 16 mg/dL [28].
Descriptive results were expressed as mean 6 standard
deviation (SD) or percentages, according the type of variable.
The efficacy measured in the continuous variables was analyzed
by an ANCOVA (ANalysis of COVAriance) model with baseline
value as a covariate. Categorical variables were analyzed using the
Fisher exact test. Primary efficacy analysis was conducted on the
intention-to-treat (ITT) population, although sensitivity analyses
were also performed on the per protocol (PP) and safety
populations. Data were analyzed using the SAS software package
version 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
Characteristics of subjects
From the 118 eligible volunteers, 104 were randomized and,
finally, data from 102 were analyzed by ITT (Fig. 1). The 14
participants excluded during the screening process were because
they did not fulfill all the inclusion criteria, or declined to
participate. Two volunteers were excluded after enrolment
because informed consent was withdrawn. Table 1 summarizes
the baseline characteristics of study participants. No relevant
differences between groups are observed at baseline.
Lipid profile
With respect to the main outcomes at 12 weeks, plasma LDL-c
in the AP group was reduced by 26.9% compared with placebo.
At 12 weeks, relative to placebo, TC was reduced by 24.97% (p,
0.05), ApoB-100 was reduced by 26.7% (p,0.05), the ratios of
TC/HDL-c by 25.5%, LDL-c/HDL-c by 27.8% and ApoB-
100/ApoA-1 by 28.6% (p,0.01). No statistically significant
changes were observed in TG and HDL-c levels (Table 2).
Additionally, we observed that the proportion of subjects achieving
LDL-c levels ,3.35 mmol/L was similar in the treatment and
placebo the groups.
Clinical parameters and glucose and insulin metabolism
At 12 weeks, compared to placebo, the body mass index (BMI)
in the AP group was reduced by 25.5% (p,0.05), with a modest
mean weight loss of 20.93 kg, (95%CI: 21.74 to 20.12; 21.37%;
P = 0.025) while other measured clinical parameters did not
change significantly during the intervention. At 12 weeks,
compared to placebo, the weight loss observed in the AP
consumption group, had no significant impact on LDL-c reduction
(P = 0.351), Apo B-100 (P = 0.208), TC/HDL-c ratio (P = 0.565),
nor on the ApoB/ApoA1 ratio (P = 0.300). This relationship was
analyzed through two complementary approaches. The first was
based on an ANCOVA model for LDL-c using the weight-loss as
covariate. This resulted in a non-significant contribution of weight-
loss (p = 0.351) to LDL-c reduction. The second approach was
based on Pearson’s correlation coefficient between LDL-c
reduction and weight-loss. The result was a small, and non-
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significant (p = 0.820) contribution. Pearson’s correlation coeffi-
cient was r = 0.024. In the AP group, energy intake and diet
composition were maintained during the study.
There were trends, albeit statistically non-significant, towards
reductions in the levels of glucose and insulin, while HOMA-IR
was higher in AP group than in placebo group (Table 3).
Dietary intake
Table 4 summarizes the dietary intake of study participants.
The intake of energy, macronutrients, cholesterol and alcohol did
not change during the 12 weeks intervention period, and no
significant differences were observed between groups, except
towards a higher mono-unsaturated fatty acid (MUFA) percentage
and lower fiber content in placebo group relative to the AP
intervention group (p,0.05). In the placebo group, the unexpect-
ed reduction in fiber consumption did not impact on LDL-c
decrease, as evaluated by the Pearson correlation coefficient
(r = 0.09, p = 0.408). An ANCOVA model for the changes in
LDL-c adjusted for fiber consumption also shows that this effect is
non-significant (p = 0.095). In addition, we observed that in the AP
group, the fiber consumption is sustained during the study, and no
impact on LDL-c concentrations was either expected or observed.
Further, the composition of the recommended 10% saturated
fatty acid (SFA) content remained unchanged in both groups in the
study.
Adverse events and product tolerance
There were no statistically significant differences between
groups with respect to adverse events reported. The AP test
product was well tolerated.
Figure 1. Flow of participants through the study. ITT: intention-to-treat; PP: per protocol, AP: Armolipid Plus.
doi:10.1371/journal.pone.0101978.g001
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Table 1. Baseline characteristics of study participants.
Variable Intervention1 (n = 51)2 Placebo (n = 51)
Age; years 49.91611.613 52.37611.15
Weight; Kg 68.81612.62 72.01615.51
Height; cm 164.6869.42 161.63612.96
BMI; Kg/m2 25.3664.07 27.9768.66
Waist circumference; cm 86.20611.76 90.40611.56
Systolic blood pressure; mmHg 122.22618.14 123.77617.64
Diastolic blood pressure; mmHg 76.49612.20 76.75611.18
Heart rate; bpm 71.4369.89 70.29610.09
10-year calculated cardiovascular risk; n (%)
Low 40 (78.4%) 42 (82.4%)
Medium 7 (13.7%) 8 (15.7%)
High 4 (7.8%) 1 (2.0%)
Smoker; n (%) 16 (31.4%) 7 (13.7%)
Gender; male, n (%) 18 (35.3%) 14 (27.5%)
1Intervention = AP = Armolipid Plus; 2 Data calculated on intention-to-treat (ITT) population; 3 Unless otherwise stated, all results are expressed as mean 6 standard
deviation (SD).
doi:10.1371/journal.pone.0101978.t001
Table 2. Lipid profile variables.
Variable Baseline Final
Change at 12 weeks
relative to baseline Treatment difference
Mean6SD Mean6SD Adjusted least square mean
[95%CI] (% change from baseline)
Adjusted least square mean




LDL-c (mg/dL) Placebo 159.28615.651 147.55626.01 212.78 [220.06; 24.03] (28.02%) 210.46 [219.81; 21.12] (26.9%) 0.029
Intervention4 155.67614.57 135.28627.15 -23.25 [-27.08; -15.34] (-14.93%)
Rest of variables
HDL-c (mg/dL) Placebo 61.10614.05 60.41614.49 -2.21 [-5.76; 1.34] (-3.62%) 1.91 [-1.50; 5.32] (3.18%) 0.268
Intervention 66.51621.20 67.70620.34 0.29 [-4.21; 3.62] (0.44%)
Total cholesterol (mg/dL) Placebo 243.43619.49 232.82628.77 -13.36 [-23.14; -3.58] (-5.49%) -12.12 [-21.28; -2.95] (-4.97%) 0.010
Intervention 243.61624.35 221.81634.37 -25.48 [-35.98; -14.99] (-10.46%)
Triglycerides (mg/dL) Placebo 115.00656.02 118.866108.76 5.72 [-25.64; 37.08] (4.97%) -6.40 [-36.26; 23.47] (-5.6%) 0.671
Intervention 107.20661.34 101.15654.42 -0.68 [-34.45; 33.09] (-0.63%)
ApoA1 (mg/dL)2 Placebo 148.82611.92 145.76612.46 -2.82 [-4.88; -0.76] (-1.89%) 3.76 [1.21; 6.31] (2.51%) 0.004
Intervention 151.88623.31 152.64624.96 0.94 [-1.14; 3.03] (0.62%)
ApoB100 (mg/dL)3 Placebo 109.02616.17 104.37615.94 -2.20 [-6.36; 1.96] (-2.02%) -6.87 [-12.07; -1.67] (-6.68%) 0.01
Intervention 104.31618.73 94.23618.53 -9.07 [-13.33; -4.81] (-8.70%)
Total cholesterol/HDL-c Placebo 3.9960.61 4.0060.67 0.00 [-0.12; 0.12] (0%) -0.21 [-0.36; -0.06] (-5.5%) 0.007
Intervention 3.8160.82 3.6060.79 -0.21 [-0.33; -0.09] (-5.51%)
LDL-c/HDL-c Placebo 2.6160.45 2.5860.51 -0.02[-0.13; 0.09] (-0.77%) -0.19 [-0.33; -0.06] (-7.8%) 0.006
Intervention 2.4460.62 2.2460.64 -0.21 [-0.32; -0.1] (-8.6%)
ApoB100/ApoA1 Placebo 0.7460.14 0.7260.14 0.00 [-0.03; 0.03] (0%) -0.06 [-0.1; -0.03] (-8.6%) 0.001
Intervention 0.7060.17 0.6360.16 -0.06 [-0.09; -0.03] (-8.57%)
1Data calculated on intention-to-treat population (n = 51) and ANCOVA model; 2ApoA1: apolipoprotein A1; 3ApoB100: apolipoprotein B100;
4Intervention = AP = Armolipid Plus.
doi:10.1371/journal.pone.0101978.t002
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Discussion
The present study is the first clinical study performed with AP
(Armolipid Plus, containing red yeast rice extract, policosanol,
berberine, folic acid, coenzyme Q10 and asthaxantine) with a
follow-up of dietary recommendations in moderately hypercho-
lesterolemic patients who were candidates for lifestyle intervention.
We verified the hypothesis that the intake of AP, in combination
with dietary recommendations, not only decreases the levels of
LDL-c but also reduces TC/HDL-c, LDL-c/HDL-c, and ApoB-
100/ApoA ratios, while serum ApoA-1 concentrations were
increased. Another unique finding of the study was that AP
consumption was associated with a modest mean weight loss of -
0.93 kg, compared with control group. With respect to weight loss,
berberine (500 mg), a constituent of the AP tablets, has been
described as having produced a mild weight loss (average 5 lb./
subject; <2.2 Kg) in obese human subjects [23]. When evaluated
as an anti-diabetic product, berberine reduced body weight and
caused a significant improvement in glucose tolerance without
altering food intake in db/db mice [29]. Similarly, berberine
reduced body weight and plasma triglycerides and improved
insulin action in Wistar rats fed a high-fat diet. Berberine down-
regulated the expression of genes involved in lipogenesis and up-
regulated those involved in energy expenditure in adipose tissue
and muscle. Berberine treatment resulted in increased AMP-
activated protein kinase (AMPK) activity in 3T3-L1 adipocytes
and L6 myotubes, increased GLUT4 translocation in L6 cells in a
phosphatidylinositol 3_kinase–independent manner, and reduced
lipid accumulation in 3T3-L1 adipocytes. These findings suggest
that berberine displays beneficial effects in the treatment of
diabetes and obesity, at least in part, via stimulation of AMPK
activity [29]. Other mechanisms proposed, following berberine
(200 mg/kg) intake, include decreased degradation of dietary
polysaccharides in high-fat-diet (HFD) mice. Berberine signifi-
cantly reduced the proportions of fecal Firmicutes and Bacter-
oidetes of total bacteria in HFD mice. In an ex-vivo trial, berberine
significantly inhibited the growth of gut bacteria under aerobic
and anaerobic conditions. In in vitro trials, berberine significantly
inhibited the growth of Lactobacillus (a classical type of
Firmicutes) under anaerobic conditions. Further, berberine
significantly increases fasting-induced adipose factor (Fiaf), a key
protein negatively regulated by intestinal microbial expression in
intestinal and/or visceral adipose tissues. Berberine significantly
increases mRNA expressions of AMPK, PGC1a, UCP2, CPT1a,
and Hadhb related to mitochondrial energy metabolism, which
may be driven by increased Fiaf expression. These results suggest
that antimicrobial activity of berberine would result in decreasing
the degradation of dietary polysaccharides, lowering potential
caloric intake and, subsequently, systemically activating Fiaf
protein, together with expression of genes related to mitochondrial
energy metabolism in visceral adipose tissues [30]. These
mechanisms could be the underlying contributions of AP to the
significant weight loss observed.
At 12 weeks, compared to placebo, the loss in body weight
observed in the AP consumption group, had no significant impact
on reduction of LDL-c, Apo B-100, total cholesterol/HDL-c ratio
nor the ApoB/ApoA1 ratio. The energy and the diet composition
Table 3. Clinical variables, glucose concentration and insulin parameters.
Variable Baseline Final
Change at 12 weeks
relative to baseline Treatment difference
Mean6SD Mean6SD Adjusted least square mean
[95%CI] (% change from baseline)
Adjusted least square mean




BMI (Kg/m2) Placebo 27.9768.661 26.7263.76 -0.15 [-1.47; 1.16] (-0.54%) -1.38 [-2.66; -0.10] (-5.5%) 0.034
Intervention2 25.3664.07 24.6163.44 -1.53 [-2.96; -0.11] (-6.03%)
Weight (Kg) Placebo 72.01 6 15.51 72.01 6 15.51 -0.14 [-1.00; 0.71] (-0.19%) -0.93 [-1.74; -0.12] (-1.37%) 0.025
Intervention 68.81 6 12.62 66.92 6 11.63 -1.08 [-1.99; -0.16] (-1.56%)
Waist circumference (cm) Placebo 90.40611.56 90.39611.16 0.65[-1.36; 2.66] (0.72%) 0.30 [-1.62; 2.23] (0.39%) 0.754
Intervention 86.20611.76 86.24610.76 0.96 [-1.17; 3.08] (1.11%)
Systolic blood pressure (mmHg) Placebo 123.77617.64 121.25617.18
Intervention 122.22618.14 122.13617.62
Diastolic blood pressure (mmHg) Placebo 76.75611.18 75.8769.96
Intervention 76.49612.20 76.45610.56
Heart rate (bpm) Placebo 70.29610.09 69.2269.73
Intervention 71.4369.89 70.3869.40
Glucose and Insulin
Glucose (mg/dL) Placebo 92.77610.30 92.78610.50 -1.79 [-5.70; 2.12] (-1.93%) -1.24 [-4.83; 2.35] (-1.42%) 0.493
Intervention 90.5869.27 90.27610.12 -3.03 [-7.10; 1.03] (-3.35%)
Insulin (pmol/L) Placebo 51.75637.66 55.57650.69 1.20 [-12.57; 14.97] (2.32%) -6.53[-23.54; 10.47] (-11.72%) 0.447
Intervention 56.68663.68 50.46635.11 -5.33 [-19.20; 8.55] (-9.40%)
HOMA-IR Placebo 1.6661.26 1.8361.88 0.1 [-0.40; 0.59] (6.02%) -0.30 [-0.91; 0.31] (-16.89%) 0.333
Intervention 1.8462.56 1.5861.14 -0.20 [-0.70; 0.30] (-10.87%)
1Data calculated on the intention-to-treat population (n = 51). Results from the ANCOVA model; 2Intervention = AP = Armolipid Plus.
doi:10.1371/journal.pone.0101978.t003
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were maintained during the study in the AP group. As such, the
diet recommendations could be said to have not influenced either
the body weight or the lipid profile changes detected. Hence, the
observed overall improvements in the metabolic parameters could
only be accounted-for by the intake of AP.
In the present study, the patients had low baseline serum LDL-c
concentrations (155.3 614.56 mg/dL) compared to other similar
studies assessing the effect of AP: 170.161.1, 174.4621.9, and
172616 ([12,31,32], respectively). Further, our patients had
higher baseline serum HDL-c concentrations and lower serum
TG concentrations than these other studies. As such, the
differences in baseline lipid concentrations could explain, at least
in part, the size of the decrease relative to baseline values of our
study. For example, our LDL-c baseline concentration was
155.3 mg/dL with a less-marked reduction of 14.9% while the
reduction in LDL-c was 25% when its baseline was 174.4 mg/dL
[31]. Hence, it is of note that the hypolipidemic impact of AP is
related to baseline TC and LDL-c concentrations i.e. greater
reductions from higher baseline concentrations.
With respect to TG, we would not expect any important
changes because the baseline levels are well within the population
reference ranges for these parameters. Again, this highlights the
different profiles of those patients included in other studies in
which the levels of both parameters were high at the commence-
ment of the study and, as a consequence, both decreased
significantly after AP treatment. The lipid profiles of the patients
in our study reflect the inclusion criteria i.e. only patients who
were candidates for lifestyle intervention were recruited. These
individuals have mild-moderate alterations in the lipid profile and,
as such, do not meet the ATPIII criteria for treatment with drugs
such as statins. The majority of our patients reflected a low, but
present, CVD risk at baseline.
Guidelines for lipid management are based, mainly, on LDL-c
concentrations [2-4]. This is despite other parameters including
the TC/HDL-c ratio being better CVD risk predictors than LDL-
c alone. The use of these ratios as CVD risk predictors is based on
several epidemiological studies which have shown that these
indices (TC/HDL-c and LDL-c/HDL-c) are better correlated
with CVD and, therefore, are better predictors of CVD than
merely lipid concentrations alone [33,34].The therapeutic goal is
to keep the TC/HDL-c ratio below 5:1 and the optimum ratio is
3.5:1 [35]. In our study, the AP group showed a TC/HDL-c ratio
of 3.660.67, which is close to the optimum ratio. Available
evidence shows that ApoB-100 and ApoA-1 and, more impor-
tantly, the ApoB-100/ApoA-1 ratio could predict cardiovascular
heart disease and stroke risk more accurately than conventional
lipid measurements; a value ,1 is recommended [36-38]. In the
present study, the lowest mean ApoB-100/ApoA-1 ratio was 0.63
and was observed in the AP consuming group at 12 weeks.
There were trends towards reductions in the levels of glucose,
insulin and HOMA-IR, which were greater in the AP group than
in placebo, albeit statistical significance was not reached.
The mechanisms underlying the hypolipidemic effect of AP
could be based on its main constituents of red yeast rice,
policosanols and berberine. As such, AP can inhibit HMG-CoA
reductase (the rate-limiting enzyme in the intra-cellular production
of cholesterol) which results in a decrease in the endogenous
production of cholesterol and an increase in its clearance. The
hypocholesterolemic effect observed can be the result of poly-
active compounds present in AP. A tablet of AP contains
policosanol (10 mg), red yeast rice (200 mg, equivalent to 3 mg
of monacolin K), berberine (500 mg), folic acid (0.2 mg),
astaxanthin (0.5 mg) and coenzyme Q10 (2 mg). At doses ranging
from 10 to 20 mg per day, policosanol lowers TC by 17% to 21%
and LDL-c by 21% to 29%, and raises HDL-c by 8% to 15% (13).
The weighted estimates of percentage change in LDL-C are
-23.7% for policosanol, about 12 mg/day (range 5–40 mg/day.
These data are obtained from 1528 patients in 29 eligible studies
[13]. Ten mg/day is the dose most studied and it has been shown
to be safe and effective. In long-term studies (2 years) with 10 mg/
day of policosanol, no significant differences were observed in the
tolerability, when compared with placebo [39].
Red yeast rice contains 14 active compounds called monacolins,
which inhibit hepatic cholesterol synthesis [40]. Of them,
monacolin K is chemically identical to lovastatin [41]. The quality
of monacolin present in red yeast depends on the strain of
Monascus purpureus and fermentation conditions. In the case of
AP, the red yeast is obtained under standardized conditions using
a specific strain of Monascus purpureus selected for optimum
production of monacolin K, the extent of which is defined and
controlled. This means that all batches of AP have the same
amount of monacolin K i.e. 3 mg per tablet. With respect to red
yeast rice, one randomized clinical trial performed in patients with
coronary artery disease, showed that an extract of red yeast rice
reduced recurrent events by 45% [42]. The participants consumed
monacolin K in a dose of between 2.5 and 3.2 mg/capsule; similar
to the dose contained in each capsule of AP (3 mg of monacolin
K)/day. When compared to the placebo group, monacolins-
treated patients experienced a more favorable percentage change
in TC (-12.45%, 95%CI: -16.19 to -8.71), LDL-c (-21.99%,
95%CI: -26.63 to -17.36), non-HDL-c (-14.67%, 95%CI: -19.22
to -10.11) [7].
A dose of 500 mg/day in mild or moderate mixed hyperlipi-
demia patients, berberine significantly reduced both LDL-c and
TG. When combined with policosanol, red yeast extract, folic
acid, astaxanthin and coenzyme Q10 (as in the AP tablet),
berberine increased its hypocholesterolemic activity and main-
tained its triglyceride-lowering and HDL-increasing activity [31].
Coenzyme Q10 is produced, to a large extent in the body
commencing from acetyl-CoA and, in a multi-step process, along
the mevalonic acid pathway. The daily 2 mg supplementation of
coenzyme Q10 provided by AP has been considered appropriate.
Further, berberine has been described as up-regulating the LDL
receptor independently of sterol regulatory element binding
protein. In experimental studies, berberine raised the LDL-R
expression through a post-transcriptional mechanism that stabi-
lizes the mRNA. This mechanism of action is distinct from the one
of statins [43]. The consequence is a significant reduction in TC
and LDL-c. These hypocholesterolemic effects of the components
of AP have been well documented, while reduction of Apo B-100
had yet to be demonstrated, until the current data. ApoB-100 is
the protein component constituent of the atherogenic very-low-
density lipoprotein (VLDL), of intermediate-density lipoprotein
(IDL) and of LDL particles, each particle containing one Apo
molecule. Hence, plasma Apo B-100 levels reflect the total
numbers of atherogenic particles [44]. For example, at 12 weeks,
compared to placebo, AP reduced LDL-c by -6.9% and ApoB-100
by -6.6%, almost exactly the same percentage reduction, and
reinforces the extent of response to treatment.
The present study reinforces the therapeutic potential of dietary
supplements such as AP. In conjunction with a recommended diet,
AP affords better control of lipid parameters and, as such, offers a
new therapeutic tool for patients with intolerance to certain
hypocholesterolemic drugs.
Some limitations need to be taken into account in the
interpretation of the results of the study. Patients recruited had
low, but present, CVD risk. It is conceivable it will be difficult to
reduce even more the low CVD risk.
Bioactive Compounds and Hypercholesterolemia
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In conclusion, AP combined with dietary recommendations
resulted in: reduced LDL-c levels, total cholesterol/HDL-c and
ApoB/ApoA1 ratios, and increased Apo A1; all being improve-
ments in CVD risk. AP is a lipid lowering compound with a
moderate weight loss effect. As part of a dietary intervention it
could be valuable for moderately hyperlipidemic patients with
excess body weight.
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